EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

Dec 11, 2023

SEC Form 4/A — Form 4/A

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-12-04

Reporting Person: Pine Michael Craig (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-04	Common Stock	M	45000.00	$12.62	Acquired	50343.00	Direct
2023-12-04	Common Stock	S	45000.00	$22.00	Disposed	5343.00	Direct
2023-12-04	Common Stock	S	1000.00	$20.79	Disposed	4343.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-04	Stock Option (Right to Buy)	$12.62	M	45000.00	Disposed	2032-01-10	Common Stock (45000.00)	Direct

Footnotes

F1: Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: This owned share transaction was inadvertently left off of the original Form 4 filing on December 6, 2023.

F3: The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.